Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Edesa Biotech, Inc. (EDSA)

$5.25 -7.24% NASDAQ: EDSA · 15-min delayed
  • MARKHAM,
  • Public · NASDAQ: EDSA
  • 17 employees
$48.6MMarket cap
$0Revenue · FY2021
-$7.2MNet income
17Employees
EDSANASDAQ
2010IPO

About Edesa Biotech, Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2021
$0
Net income
-$7.2M
Total assets
$13.5M
Market cap
$48.6M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Operating income
-$7.9M
Income tax
$800
Net income
-$7.2M
EPS (basic)
$-1.27

Balance sheet

Total assets
$13.5M
Current assets
$11.5M
Total liabilities
$1.1M
Current liabilities
$1.1M
Shareholders’ equity
$12.5M

Cash flow

Operating cash flow
-$7.3M
Investing cash flow
-$9.7M
Financing cash flow
$17.0M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: EDSA
$5.25 -7.24%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$0.80 $18.27

52-week range

Market cap
$48.6M
Shares outstanding
9.2M
Open
Day range
Prev close
Volume
IPO date
Jun 9, 2010

Edesa Biotech, Inc. (EDSA) Stock Price

  • Reported a net loss of $7.2M in FY2021.
  • Trading 71% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Edesa Biotech, Inc..

Write a review
Newsroom

News about Edesa Biotech, Inc.

News & sentiment via Polygon.io

FAQ

Edesa Biotech, Inc.: frequently asked questions

Is Edesa Biotech, Inc. an American company?

Edesa Biotech, Inc. is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Edesa Biotech, Inc. publicly traded?

Yes — Edesa Biotech, Inc. is a publicly traded company. Its stock trades under the ticker symbol EDSA on the NASDAQ.

What does Edesa Biotech, Inc. do?

Edesa Biotech, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →